Similarly, the HRD scores for NTHL1-het cancers were significantly lower than those observed in the PALB2 associated cancers (median 21.5 vs. 74.5, P < 0.001) or the RAD51C associated cancers (median 21.5 vs. 58, P = 0.01), and not significantly different to those observed in sporadic cancers (median 21.5 vs. 27, P = 0.79) (Fig. 1d). This evidence concerns the gene PALB2 and cancer.